The 2021 SABCS opens today, the first of four days of world-class programming highlighting the highest quality, state-of-the-art clinical, translational, and basic research in breast cancer.
Whether you’re attending virtually or in person here in San Antonio, this year’s symposium — the first ever hybrid SABCS — features all the great science you’ve come to expect from the world’s largest and longest running symposium designed specifically for breast cancer clinicians and researchers.
“No matter how you attend, you do not want to miss the hot topics and hot-off-the-press trial results that will be presented this week, including the latest findings on oral selective estrogen receptor downregulators (SERDs) for the treatment of ER-positive breast cancer, important updates on immunotherapy, and emerging data on new anti-HER2 therapies,” said Virginia Kaklamani, MD, who serves as SABCS Co-Director alongside Carlos Arteaga, MD.
“We will also hear a lot about progress in precision medicine, including ways to potentially tailor our treatments based on genomic information of the tumor,” Dr. Kaklamani said. “And, of course, we will once again have a COVID session exploring how the pandemic has impacted our patients and ourselves over the past year.”
As always, SABCS is designed to not only give attendees what they want to learn, but also a variety of options for how they want to learn, with a comprehensive schedule of cutting-edge science presented in general sessions, plenary and award lectures, mini-symposia, poster presentations, debates, educational sessions, workshops, forums, and panel and case discussions.
Following are highlights of today’s schedule. Check the online program or mobile app for the complete and most up-to-date program schedule. And be sure to check out the SABCS Meeting News each day for program highlights and select session coverage.
7:45 am – 8:00 am CT
Welcome and Opening Remarks – Hall 3
SABCS Co-Directors Carlos Arteaga, MD, and Virginia Kaklamani, MD
8:00 am – 10:45 am CT
General Session 1 – Hall 3
- GS1-00 Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial
- GS1-01 KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses
- GS1-02 Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
- GS1-05 Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study
- GS1-06 A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer
- GS1-07 Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial
- GS1-08 CCTGMA.32, a phase III randomized double-blind placebo controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438)
- GS1-09 Inhibition of GPX4 induces preferential death of p53-mutant triple-negative breast cancer cells
- GS1-10 Clinical utility of molecular tumor profiling: Results from the randomized trial SAFIR02-BREAST
11:00 am – 1:00 pm CT
Special Session: COVID – 19 and Cancer – Hall 4A
- Living in the COVID generation – Vaccinations and Patient Perspectives
- How COVID changed “everything”
- Impact of COVID across Cancer Continuum
Clinical Research Workshop: From Study Design to Scientific Presentation – Stars at Night Ballroom 1&2
Basic Research Workshop: Basic Science for Breast Oncologists – Stars at Night Ballroom 3&4
1:00 pm – 4:00 pm CT
Special Session: Trust in Science and Healthcare – Hall 3
- Panel 1: Equity in Research and Patient Care
- Panel 2: Diversity in Clinical Trials
4:00 pm – 5:00 pm CT
Susan G. Komen® Brinker Awards for Scientific Distinction Lectures – Hall 3
- Brinker Award for Scientific Distinction in Basic Science – Carlos Caldas, MD
- Brinker Award for Scientific Distinction in Clinical Research – Judy Garber, MD, MPH